文献速递心血管MR

钆布醇用于心脏MRI:Anderson-Fabry病患者不同剂量下心肌T1弛豫时间与主观图像质量比较

Gadopiclenol for Cardiac MRI: Comparison of Myocardial T1 Relaxation Times and Subjective Image Quality at Different Doses in Patients With Anderson-Fabry Disease.
PubMed 文献 · Invest Radiol · 2026-09-25

这是一项单中心回顾性可行性研究,纳入32例Anderson-Fabry病(AFD)患者,在3T心脏MRI下比较0.05 mmol/kg与0.1 mmol/kg钆布醇(gadopiclenol)的心肌延迟强化(LGE)图像质量及T1弛豫变化。结果显示两种剂量均获诊断性图像质量,0.1 mmol/kg组定量与定性对比效应略优,但0.05 mmol/kg组仍技术可行。作者认为减量至0.05 mmol/kg可能可行,但需前瞻研究验证。

要点

  • 0.05 mmol/kg钆布醇可获得高质量LGE图像,提示剂量减半在CMR可能可行
  • 0.1 mmol/kg组在总图像质量和血池-心肌对比度评分上略高,但差异小
  • 节段层面较高剂量在未受累心肌ΔR1显著增大(P=0.003),受累心肌区不显著

核心结论

  • 在3T AFD队列中,0.05 mmol/kg和0.1 mmol/kg钆布醇均可获得高主观LGE图像质量,0.1 mmol/kg组定性定量对比效应略强,但0.05 mmol/kg仍技术可行,支持将钆布醇剂量减至0.05 mmol/kg用于CMR可能可行,但需前瞻性研究验证。

研究设计与样本

  • 回顾性单中心研究,筛选133次CMR,最终32例AFD患者入组
  • 患者分两组:0.05 mmol/kg组(实际范围0.04-0.07 mmol/kg,n=16)和0.1 mmol/kg组(实际范围0.08-0.11 mmol/kg,n=16)
  • 采用3T CMR,含前后对比T1 mapping,三位阅片者独立用5分Likert量表评估LGE图像质量
  • 定量分析包括前后心肌T1、ΔT1及弛豫率ΔR1,节段水平用混合效应模型调整采像延迟

关键影像表现/征象

  • 两种剂量下LGE图像均呈诊断性质量,0.1 mmol/kg组总体图像质量及血池-心肌对比度评分略高
  • 0.05 mmol/kg组大多数检查被评为良好至极好
  • 注射前心肌T1两组无差异(1132.39±61.91 ms vs 1132.84±53.39 ms,P=0.98)
  • 0.1 mmol/kg组注射后T1缩短更明显
  • 节段分析显示较高剂量在所有节段ΔR1均较大,其中未受累节段显著(Δ=-0.37 1/s,P=0.003),受累节段不显著(Δ=-0.18 1/s,P=0.48)

临床应用与阅片要点

  • 对AFD患者进行3T心脏MRI时,0.05 mmol/kg钆布醇可作为剂量选择,但需注意0.1 mmol/kg组对比效应稍强
  • 报告LGE质量时,可参考0.05 mmol/kg组大多数检查仍评为良好至极好,支持低剂量使用
  • 识别未受累心肌节段时,较高剂量ΔR1显著增加,可能更利于检测早期或轻微心肌受累

局限性

  • 回顾性单中心研究
  • 样本量仅32例,且两组各16例
  • 剂量分配非随机(按实际给药记录分组),存在选择偏倚风险
  • 结果基于AFD患者群体,推广至其他心脏病需谨慎

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Due to its high relaxivity, the second-generation gadolinium-based contrast agent gadopiclenol has been shown to provide equally high image quality with reduced gadolinium dose. Gadopiclenol has not yet been approved for cardiac magnetic resonance imaging (CMR). The aim of this observational feasibility study was to assess late gadolinium enhancement (LGE) image quality and myocardial T1 shortening after application of gadopiclenol at 2 dose levels in patients with Anderson-Fabry disease (AFD) undergoing 3 T CMR.

MATERIALS AND METHODS: In this retrospective single-center study, 133 CMR examinations were screened, and 32 patients met the eligibility criteria of AFD, gadopiclenol administration, documented contrast dose, and complete precontrast and postcontrast T1 mapping. Patients were grouped by dose (0.05 mmol/kg group, ranging from 0.04 to 0.07 mmol/kg vs. 0.1 mmol/kg group, ranging from 0.08 to 0.11 mmol/kg; n=16 each). Three readers independently rated LGE image quality using a 5-point Likert scale. Quantitative analysis included precontrast and postcontrast myocardial T1, ΔT1, and the relaxation rate ΔR1. Segment-level postcontrast effects were analyzed using a mixed-effects model adjusting for acquisition delay.

RESULTS: Both dose levels, the 0.05 mmol/kg and the 0.1 mmol/kg gadopiclenol, resulted in diagnostic examinations with high subjective LGE image quality. The 0.1 mmol/kg group showed slightly higher ratings for overall image quality and bloodpool-to-myocardium contrast, although absolute differences were small and most examinations in the 0.05 mmol/kg group were still rated good to excellent. Native myocardial T1 did not differ between groups (1132.39±61.91 ms vs. 1132.84±53.39 ms; P=0.98). Postcontrast T1 shortening was greater at 0.1 mmol/kg. In segment-level analysis, the higher dose showed greater ΔR1 in all segments, which was statistically significant in unaffected segments (Δ=-0.37 1/s; P=0.003), but not in affected segments (Δ=-0.18 1/s; P=0.48).

CONCLUSIONS: In this retrospective 3 T AFD cohort, gadopiclenol provided high LGE image quality at both dose levels. While 0.1 mmol/kg produced slightly stronger qualitative and quantitative contrast effects, 0.05 mmol/kg remained technically feasible. These preliminary findings support that dose reduction to 0.05 mmol/kg gadopiclenol may be feasible in CMR. However, validation through prospective studies is needed before recommending lower-dose gadopiclenol broadly in routine CMR.

来源:Invest Radiol,查看原文。版权归原作者所有。

引用

  1. Kollmann, Huflage, Dazeh, et al. Gadopiclenol for Cardiac MRI: Comparison of Myocardial T1 Relaxation Times and Subjective Image Quality at Different Doses in Patients With Anderson-Fabry Disease. Invest Radiol. 2026. PMID: 42786928. doi:10.1097/RLI.0000000000001314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。